39

RecensMedical, Inc.

394420 · KQ · Healthcare / Medical Devices

4,470.00KRW-300.00 (-6.29%)

Price History

Full chart

Market Stats

Previous Close4,770.00
Open4,770.00
Day Range4,450.00 – 4,880.00
52-Week Range8,060.00 – 39,900.00
Volume67.61K
Market Cap95.05B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
50-Day Avg10,323.40
200-Day Avg17,374.69

About

RecensMedical, Inc. operates as a medical device company specializing in precision cooling therapy and transdermal drug delivery solutions. The company engages in the development of precision medical cooling device in the fields of ophthalmology and dermatology. The company's products include OcuCool, a hand-held, cooling anesthesia device that provides rapid and controlled cooling to the conjunctiva and sclera, and TargetCool, a handheld device that delivers rapid, precise, and controlled cooling to the skin tissue for the temporary reduction of pain, swelling, inflammation, and hematoma from minor surgical procedures, minor sprains or other minor sports injuries. Additionally, it offers TargetCool+, a spray syringe; and VetEase, a spray syringe for animals. Its portfolio of clinical program includes ocular anesthesia, actinic keratosis, eczema, rosacea, prurigo nodularis, and atopic dermatitis. The company was founded in 2016 and is based in Hwaseong-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Gun-ho Kim
  • HeadquartersDongtan SK V1 Center, Hwaseong-si, South Korea, 18468, Korea
  • Websitehttps://recensmedical.co.kr

Leadership

  • Mr. Gun-ho KimCo-CEO, CTO & Inside Director · b. 1980
  • Ms. Uikyung ChoiCo-CEO & Inside Director · b. 1971
  • Mr. SeWang KimMD, CFO & Inside Director · b. 1981
  • Mr. Yongjin LeeMD & Marketing Director · b. 1981
  • Mr. Yujin ChoMD & Production Headquarters Manager · b. 1971

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue281.76M5.77B6.26B8.83B
Growth (%)-+1948.03%+8.47%+41.05%
Cost of Revenue169.18M2.73B4.89B4.50B
Gross Profit112.58M3.04B1.37B4.33B
Gross Margin39.96%52.65%21.95%49.06%
Operating Expense20.36B15.62B15.53B14.97B
Operating Income-20.24B-12.58B-14.16B-10.64B
Operating Margin-7185.17%-218.07%-226.24%-120.52%
EBITDA-38.36B-3.98B-3.56B-16.20B
EBITDA Margin-13615.73%-69.03%-56.84%-183.51%
Net Income-40.99B-7.57B-7.84B-19.12B
Net Income Margin-14549.34%-131.22%-125.31%-216.56%
R&D2.87B2.84B2.42B3.41B
R&D as % of Total Revenue1017.55%49.14%38.69%38.63%
Interest Expense2.21B3.06B3.90B2.41B
Interest Expense % of Total Revenue782.97%53.10%62.27%27.27%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets25.64B15.23B20.10B12.01B
Total Liabilities103.93B99.20B110.66B5.03B
Total Equity-78.30B-83.97B-90.56B6.98B
Cash9.40B2.57B5.30B987.51M

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-22.02B-13.28B-9.73B-8.59B
Capital Expenditure902.08M253.49M487.18M806.84M
Free Cash Flow-22.92B-13.53B-10.22B-9.40B
FCF to OCF104.10%101.91%105.01%109.39%

Key Statistics & Ratios

Market Cap95.05B
Enterprise Value99.11B
Trailing P/E0.00
Forward P/E0.00
Price / Sales14.58
Price / Book5.38
Revenue (TTM)6.52B
Gross Profit (TTM)3.47B
EBITDA-11.12B
Profit Margin-169.40%
Operating Margin-165.38%
Return on Equity0.00%
Return on Assets0.00%
Shares Outstanding10.85M
Shares Float6.39M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%